UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 成人における全身性硬化症（強皮症）の診断および鑑別診断diagnosis and differential diagnosis of systemic sclerosis scleroderma in adults [show details]
…prompt consideration of other fibrosing illnesses . Antitopoisomerase I (anti-Scl-70) antibody. Anti-DNA topoisomerase I (Scl-70) antibodies are generally associated with diffuse cutaneous SSc (dcSSc) and …
2. 抗核抗体の測定および臨床的意義measurement and clinical significance of antinuclear antibodies [show details]
…antigens used in solid phase assays may include all or some of the following: Ro, La, Sm, U1 RNP, Scl-70, PM-Scl, Jo-1, centromere, histone, ribosomal P, and DNA. Diluted human serum is incubated with the…
3. 強皮症の概要および分類overview and classification of scleroderma disorders [show details]
…percent), and in healthy persons (7 percent). Unlike testing for antibodies to topoisomerase I (anti-Scl-70), a commercial assay for anti-topoisomerase II is not available. It has been observed that other…
4. 成人における全身性硬化症（強皮症）の臨床症状の概要overview of the clinical manifestations of systemic sclerosis scleroderma in adults [show details]
…SSc. There are conflicting data regarding whether the presence of antibodies to topoisomerase-I (Scl-70) identifies a population of SSc patients who are more likely to have, or to develop, cancer . …
5. レイノー現象の臨床症状および診断clinical manifestations and diagnosis of the raynaud phenomenon [show details]
…. A six-year study evaluated the efficacy of ANA and anticentromere and antitopoisomerase (anti-Scl-70) testing in predicting the subsequent development of an autoimmune rheumatic disease among 85 patients …

English Journal

Pulmonary hypertension in Spanish patients with systemic sclerosis. Data from the RESCLE registry.

García-Hernández FJ, Castillo-Palma MJ, Tolosa-Vilella C, Guillén-Del Castillo A, Rubio-Rivas M, Freire M, Vargas-Hitos JA, Todolí-Parra JA, Rodríguez-Carballeira M, Espinosa-Garriga G, Colunga-Argüelles D, Ortego-Centeno N, Trapiella-Martínez L, Rodero-Roldán MM, Pla-Salas X, Perales-Fraile I, Pons-Martín Del Campo I, Chamorro AJ, Fernández-de la Puebla Giménez RA, Madroñero-Vuelta AB, Ruíz-Muñoz M, Fonollosa-Pla V, Simeón-Aznar CP, , , .
Clinical rheumatology. 2019 Apr;38(4)1117-1124.
Our objective was to evaluate the pulmonary hypertension (PH) data for Spanish patients with systemic sclerosis (SSc), define the PH types and determine the associated factors. Descriptive study of PH-related data from the multicentre RESCLE registry. Estimated systolic pulmonary artery pressure (es
PMID 30535994

Scleroderma renal crisis (SRC): risk factors for an increasingly rare organ complication.

Moinzadeh P, Kuhr K, Siegert E, Blank N, Sunderkoetter C, Henes J, Krusche M, Schmalzing M, Worm M, Schmeiser T, Günther C, Aberer E, Susok L, Riemekasten G, Kreuter A, Zeidler G, Juche A, Hadjiski D, Mueller-Ladner U, Gaebelein-Wissing N, Distler JHW, Sárdy M, Krieg T, Hunzelmann N.
The Journal of rheumatology. 2019 Apr;().
Scleroderma renal crisis (SRC) is a severe life-threatening manifestation in patients with systemic sclerosis (SSc). However, the knowledge about risk factors for SRC is limited. We here determined the frequency of SRC and identified risk factors for the prediction of SRC. Based on regular follow-up
PMID 30936287

Prognostic properties of anti-topoisomerase antibodies in patients identified by the ACR/EULAR 2013 systemic sclerosis criteria.

Boonstra M, Ninaber MK, Ajmone Marsan N, Huizinga TWJ, Scherer HU, de Vries-Bouwstra JK.
Rheumatology (Oxford, England). 2019 Apr;58(4)730-732.
PMID 30690619

Japanese Journal

間質性肺炎増悪が抗トポイソメラーゼI抗体陽転化に先行した抗セントロメア抗体陽性全身性強皮症の1例 (特集膠原病)

石月翔一郎,沖山奈緒子,齊藤明允,藤本学
皮膚科の臨床 59(2), 149-152, 2017-02
NAID 40021081761

Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting

Kuwana Masataka
日本医科大学雑誌 84(2), 56-63, 2017
… <p>The presence of circulating anti-nuclear antibodies (ANAs) is a hallmark of immune dysregulation in patients with systemic sclerosis (SSc). … Currently, a variety of SSc-specific ANAs, including anticentromere, anti-topoisomerase I, and anti-RNA polymerase III antibodies, have been well characterized, and their commercial kits are available worldwide. …
NAID 130006886452

P1-39　強皮症症例における末梢血免疫担当細胞のサブセット解析

小林聖未,岡村僚久,山本一彦,藤尾圭志,庄田宏文,永渕泰雄,大久保麻衣,杉森祐介,竹島雄介,太田峰人,岩崎由希子,住友秀次
日本臨床免疫学会会誌 40(4), 307c-307c, 2017
… SSc）症例における末梢免疫担当細胞サブセットの特徴およびそれらの臨床的特徴との関連を明らかにする．【方法】SSc 19例および年齢・性別をマッチした健常者 11例の末梢血より単核球を分離し，Flow cytometryを用いてサブセット解析を行った．SSc例は9例が抗topoisomerase-I抗体（Anti-topoisomerase I antibody; …
NAID 130006219499